Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
NextDecade Corporation Q4 2025 Earnings Call - Trains 4 and 5 FID funded; early cargo sales blunt market exposure
NextDecade used 2025 to lock down commercial contracts, secure FIDs for trains 4 and 5, and fund the equity with a back-leveraging structure that preserves common shares. Phase 1 construction is track...
- NextDecade achieved FIDs on trains 4 and 5 in September and October 2025 and fully funded each train using approximately 60% debt and 40% equity at FID.
- NextDecade funded its NextDecade-level equity commitments (~$2.4 billion) through roughly $2.7 billion in term loans plus over $200 million of cash, using a back-leveraging approach (Super FinCo and FinCo facilities) designed to avoid material dilution to common shares.
- Commercial progress: five 20-year SPAs totaling 7.2 MTPA were executed in 2025 (TotalEnergies, Aramco, JERA, EQT, ConocoPhillips), adding to the 1.9 MTPA SPA with ADNOC from 2024, for 9.1 MTPA of SPAs on trains 4 and 5 with fixed liquefaction fees of about $1.2 billion annually before escalation.
- +11 more takeaways
ADT Q4 2025 Earnings Call - Origin AI acquisition positions ADT to shift from reactive alarms to proactive AI sensing
ADT delivered a steady 2025 with results inside guidance, strong cash generation, and an aggressive capital-return stance, but management paints 2026 as a deliberate transition year. The company is in...
- ADT reported full-year 2025 revenue of $5.1 billion, up 5%, and adjusted EBITDA of $2.68 billion, up 4%.
- Adjusted EPS rose 19% to $0.89 per share in 2025, helped by EBITDA growth and lower share count.
- Adjusted free cash flow, including swaps, grew 16% in 2025 and has more than doubled since 2021; ADT returned nearly $800 million to shareholders in 2025 (about $600 million buybacks, $187 million dividends).
- +12 more takeaways
UroGen Pharma Full Year 2025 Earnings Call - Permanent J-code accelerates Zusduri launch; >$1B peak potential
UroGen framed 2025 as a launch year and 2026 as the proof point. Zusduri recorded $15.8 million in 2025 and, with a permanent J-code effective January 1, 2026, management reports clear early accelerat...
- Permanent J-code for Zusduri went into effect January 1, 2026, and management reports a visible step-up in adoption and utilization in early 2026.
- Zusduri net product revenue was $15.8 million in 2025, reflecting an early foundational launch during the miscellaneous J-code period.
- Jelmyto net product revenue was $94 million in 2025; total company revenue was $109.8 million, up 21% year-over-year from $90.4 million in 2024.
- +11 more takeaways
SQM Q4 2025 Earnings Call - Nova Andino Hits Record Lithium Volumes as Prices Inflect Higher
SQM closed 2025 with a clear operational pivot: the newly formed Nova Andino Litio JV with Codelco is running at capacity and delivered record quarterly lithium sales, while realized lithium prices in...
- SQM reported full-year 2025 revenues of $44.6 billion and net income of $588 million.
- SQM and Codelco formalized the Nova Andino Litio JV, enabling long-term lithium production from Salar de Atacama; Nova Andino is running at full capacity.
- Nova Andino sold over 66,000 metric tons of lithium in Q4 2025, more than 50% year-over-year growth and a quarterly record.
- +12 more takeaways
StealthGas Inc. Fourth Quarter 2025 Earnings Call - Debt-Free Balance Sheet, Strong Profits Despite Idle MGC
StealthGas closed 2025 with one of its strongest financial pictures in years, reporting adjusted annual net income of about $65.6 million and achieving a debt-free balance sheet after $350 million of ...
- StealthGas reported adjusted net income of $65.6 million for 2025, the second highest in company history, and adjusted quarterly net income of $13.3 million for Q4 2025.
- Q4 2025 revenues were $39.4 million, down 9.4% year on year; full-year revenues were $173.0 million, up 3.5% YoY.
- The company completed strategic deleveraging in 2025, repaying $86 million that year and $350 million since 2023, and entered 2026 with zero bank debt on the consolidated fleet.
- +14 more takeaways
Venture Global LNG Q4 2025 Earnings Call - Rapid scale-up clears path to $5.2B-$5.8B 2026 EBITDA
Venture Global used Q4 to turn promises into production. The company has quickly moved from IPO to large scale output, nearly tripling revenue and EBITDA year over year, while simultaneously building ...
- Venture Global went public in January 2025 and quickly commercialized assets, with Calcasieu Pass reaching commercial operations in April 2025.
- Q4 2025 revenue was $4.4 billion, up from $1.5 billion in Q4 2024; full year 2025 revenue was $13.8 billion versus $5.0 billion in 2024.
- Consolidated Adjusted EBITDA in Q4 2025 was $2.0 billion, a 191% increase from $688 million in Q4 2024; full year 2025 Consolidated Adjusted EBITDA was $6.3 billion.
- +17 more takeaways
Zymeworks Q4 2025 Earnings Call - Zanidatamab clinical win pushes Ziihera toward potential approval while $250M royalty note fuels buybacks and BD optionality
Zymeworks leaned into a watershed clinical moment and a creative financing move this quarter. Partners Jazz and BeiGene presented HERIZON-GEA-01 data showing zanidatamab combinations produced a median...
- HERIZON-GEA-01 data presented by partners Jazz and BeiGene showed zanidatamab plus chemotherapy, with or without a checkpoint inhibitor, achieved median PFS > 1 year and median overall survival > 2 years in first-line HER2-positive metastatic or locally advanced GEA.
- Jazz expects to submit a supplemental BLA under the FDA Real-Time Oncology Review program in Q1 2026 and anticipates potential approval and launch of zanidatamab (Ziihera) in GEA in H2 2026, subject to FDA review; an additional interim median OS analysis is expected by mid-2026.
- Zanidatamab has Breakthrough Therapy designation for HER2-positive GEA and the HERIZON-GEA-01 benefit was consistent across clinically relevant subgroups, irrespective of PD-L1 exploratory results.
- +12 more takeaways
AAON, Inc. Q4 2025 Earnings Call - BASX Demand Surges to $1.3B Backlog, Margins Hit by Ramping and ERP Headwinds
AAON closed 2025 on clear top-line strength, driven by an accelerating BASX data center business and a resilient AAON branded commercial segment. BASX bookings and backlog exploded, but the company pa...
- BASX momentum is real: full-year BASX branded sales rose 143% to $548 million, and BASX backlog reached $1.3 billion, up 141% year-over-year and 45% sequentially.
- BASX book-to-bill was 2.4 for 2025, signaling strong order intake versus current production capacity.
- Q4 net sales were $424.2 million, up 42.5% year-over-year; BASX Q4 sales grew 109.1% to $106.1 million, AAON branded Q4 sales rose 9.5%.
- +12 more takeaways
TGS Q4 2025 Earnings Call - Bond-Funded Buildout Puts Perito Moreno Expansion and $2.9bn NGL Project on Fast Track
TGS reported a softer Q4 2025 profit but materially stronger liquidity after a $500 million, 10-year bond that closed oversubscribed and lifted cash to ARS 1,808 billion. The quarter shows two stories...
- TGS issued a $500 million, 10-year bond at an 8% yield in November, the deal was oversubscribed with an order book of $1.3 billion.
- Proceeds from the bond are financing roughly $780 million of CapEx tied to the Perito Moreno pipeline expansion plus final regulated pipeline tranches adding a combined 26 million cubic meters per day of capacity.
- Company cash rose by ARS 864 billion in Q4 to ARS 1,808 billion (about $1.25 billion at the official rate), driven mainly by the bond proceeds.
- +12 more takeaways
Turning Point Brands Fourth Quarter 2025 Earnings Call - White pouch surge forces front-loaded investment
Turning Point Brands closed 2025 on a clear inflection point, driven by a rapid ramp of Modern Oral white nicotine pouches. Consolidated revenue rose 29% to $121 million, with Modern Oral net revenue ...
- Revenue up 29% year-over-year to $121.0 million in Q4 2025, driven primarily by Modern Oral (white pouch) growth.
- Modern Oral net revenue was $41.3 million in Q4, a 266% year-over-year increase; Modern Oral gross sales rose 337% year-over-year.
- Company is initiating 2026 Modern Oral guidance: gross sales $220 million to $240 million, net sales $180 million to $190 million.
- +12 more takeaways